Genetic leukoencephalopathies (GLEs) are a group of white matter abnormalities with heterogeneous radiological and phenotypic features. Although these conditions have mostly been described in children, adult-onset cases are increasingly recognized owing to the widespread use of neuroimaging and advances in molecular genetic testing. The disease course is often progressive with a varied spectrum of presentations, trapping neurologists in the dilemma of differential diagnosis. Movement disorders are among the most common symptoms, and their diversity makes diagnosis challenging. In this review, we focus on adult-onset GLEs with movement disorders and offer a step-by-step diagnostic approach by clarifying the phenomenology of movement, advising investigations for acquired causes, describing the clinical and radiological clues to each disease, emphasizing the limitations of advanced molecular testing, and discussing the future application of artificial intelligence. We provide a list summarizing the leukoencephalopathies associated with different categories of movement disorders. In addition to guiding clinicians on how to narrow the list of differential diagnoses with the tools currently available, another aim of this review is to emphasize the inevitable trend toward applying advanced technology in diagnosing these difficult diseases.
Neurodegenerative disorders associated with high basal ganglia iron are known by the overarching term of ‘NBIA’ disorders or ‘neurodegeneration with brain iron accumulation’. Discovery of their individual genetic bases was greatly enabled by the collection of DNA and clinical data in just a few centers. With each discovery, the remaining idiopathic disorders could be further stratified by common clinical, radiographic or pathological features to enable the next hunt. This iterative process, along with strong and open collaborations, enabled the discoveries of PANK2, PLA2G6, C19orf12, FA2H, WDR45, and COASY gene mutations as underlying PKAN, PLAN, MPAN, FAHN, BPAN, and CoPAN, respectively. The era of Mendelian disease gene discovery is largely behind us, but the history of these discoveries for the NBIA disorders has not yet been told. A brief history is offered here.
Citations
Citations to this article as recorded by
Mitochondrial iron deficiency triggers cytosolic iron overload in PKAN hiPS-derived astrocytes Paolo Santambrogio, Anna Cozzi, Chiara Balestrucci, Maddalena Ripamonti, Valeria Berno, Eugenia Cammarota, Andrea Stefano Moro, Sonia Levi Cell Death & Disease.2024;[Epub] CrossRef
Iron Dyshomeostasis in Neurodegeneration with Brain Iron Accumulation (NBIA): Is It the Cause or the Effect? Francesco Agostini, Bibiana Sgalletta, Marco Bisaglia Cells.2024; 13(16): 1376. CrossRef
Metabolic impairments in neurodegeneration with brain iron accumulation Agata Wydrych, Barbara Pakuła, Justyna Janikiewicz, Aneta M. Dobosz, Patrycja Jakubek-Olszewska, Marta Skowrońska, Iwona Kurkowska-Jastrzębska, Maciej Cwyl, Mariola Popielarz, Paolo Pinton, Barbara Zavan, Agnieszka Dobrzyń, Magdalena Lebiedzińska-Arciszew Biochimica et Biophysica Acta (BBA) - Bioenergetics.2024; : 149517. CrossRef
COASY Protein-Associated Neurodegeneration: Report from India Rohan R. Mahale, Raviprakash Singh, Pavankumar Katragadda, Hansashree Padmanabha Annals of Indian Academy of Neurology.2023; 26(5): 834. CrossRef
Patients with Parkinson’s disease (PD) face a multitude of gastrointestinal (GI) symptoms, including nausea, bloating, reduced bowel movements, and difficulties with defecation. These symptoms are common and may accumulate during the course of PD but are often under-recognized and challenging to manage. Objective testing can be burdensome to patients and does not correlate well with symptoms. Effective treatment options are limited. Evidence is often based on studies in the general population, and specific evidence in PD is scarce. Upper GI dysfunction may also interfere with the pharmacological treatment of PD motor symptoms, which poses significant management challenges. Several new less invasive assessment tools and novel treatment options have emerged in recent years. The current review provides an overview and a practical approach to recognizing and diagnosing common upper and lower GI problems in PD, e.g., dyspepsia, gastroparesis, small bowel dysfunction, chronic constipation, and defecatory dysfunction. Management aspects are discussed based on the latest evidence from the PD and general populations, with insights for future research pertaining to GI dysfunction in PD.
Citations
Citations to this article as recorded by
Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients Agnieszka Gorecka‐Mazur, Anna Krygowska‐Wajs, Agata Furgala, Jiaqi Li, Benjamin Misselwitz, Wojciech Pietraszko, Borys Kwinta, Bahtiyar Yilmaz Neurogastroenterology & Motility.2024;[Epub] CrossRef
Clinical diagnosis, prevention, and treatment of neurodyspepsia syndrome using intelligent medicine Jingyu Zhu, Wei Meng, Liang Liu, Peixin Hu, Yuling Liang, Wenwen Zhu, Xiaoyan Zhu Open Life Sciences.2024;[Epub] CrossRef
Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning Rebecca Ting Jiin Loo, Olena Tsurkalenko, Jochen Klucken, Graziella Mangone, Fouad Khoury, Marie Vidailhet, Jean-Christophe Corvol, Rejko Krüger, Enrico Glaab, Geeta Acharya, Gloria Aguayo, Myriam Alexandre, Muhammad Ali, Wim Ammerlann, Giuseppe Arena, Mi Parkinsonism & Related Disorders.2024; 126: 107054. CrossRef
Acupuncture for constipation in Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials Zhao Li, Qun Niu, Kai Yang, Keni Zhao, Shao Yin, Fengya Zhu Medicine.2024; 103(29): e38937. CrossRef
Alpha Synuclein Toxicity and Non-Motor Parkinson’s Gabriella M. Mazzotta, Carmela Conte Cells.2024; 13(15): 1265. CrossRef
Novel strategies in Parkinson’s disease treatment: a review Charles L. Mitchell, Dmitry Kurouski Frontiers in Molecular Neuroscience.2024;[Epub] CrossRef
Advice to People with Parkinson’s in My Clinic: Probiotics and Prebiotics Jia Wei Hor, Tzi Shin Toh, Shen-Yang Lim, Ai Huey Tan Journal of Parkinson's Disease.2024; : 1. CrossRef
Unmasking bowel obstruction in a Parkinson’s patient: the influence of cognitive bias in frailty medicine Harvey Stevenson, Daniele Ramsay, Waseem Jerjes Oxford Medical Case Reports.2024;[Epub] CrossRef
Comparing Essential Tremor with and without Soft Dystonic Signs and Tremor Combined with Dystonia: The TITAN Study Roberto Erro, Giulia Lazzeri, Carmen Terranova, Giulia Paparella, Angelo Fabio Gigante, Rosa De Micco, Luca Magistrelli, Francesca Di Biasio, Francesca Valentino, Vincenzo Moschella, Andrea Pilotto, Marcello Esposito, Enrica Olivola, Maria Chiara Malaguti Movement Disorders Clinical Practice.2024; 11(6): 645. CrossRef
Clinical correlates of “pure” essential tremor: the TITAN study Roberto Erro, Giulia Lazzeri, Angelo Fabio Gigante, Andrea Pilotto, Luca Magistrelli, Matteo Bologna, Carmen Terranova, Enrica Olivola, Carlo Dallocchio, Vincenzo Moschella, Francesca Valentino, Francesca Di Biasio, Alessandra Nicoletti, Rosa De Micco, Li Frontiers in Neurology.2023;[Epub] CrossRef
Patient-Friendly Discharge Summaries in Korea Based on ChatGPT: Software Development and Validation Hanjae Kim, Hee Min Jin, Yoon Bin Jung, Seng Chan You Journal of Korean Medical Science.2024;[Epub] CrossRef
A Survey of Clinicians' Views of the Utility of Large Language Models Matthew Spotnitz, Betina Idnay, Emily R. Gordon, Rebecca Shyu, Gongbo Zhang, Cong Liu, James J. Cimino, Chunhua Weng Applied Clinical Informatics.2024; 15(02): 306. CrossRef
Performance of ChatGPT 3.5 and 4 as a tool for patient support before and after DBS surgery for Parkinson’s disease Ana Lúcia Oliveira, Miguel Coelho, Leonor Correia Guedes, Maria Begoña Cattoni, Herculano Carvalho, Pedro Duarte-Batista Neurological Sciences.2024;[Epub] CrossRef
Can ChatGPT diagnose my collapsing dog? Samira Abani, Steven De Decker, Andrea Tipold, Jasmin Nicole Nessler, Holger Andreas Volk Frontiers in Veterinary Science.2023;[Epub] CrossRef
Bias and Inaccuracy in AI Chatbot Ophthalmologist Recommendations Michael C Oca, Leo Meller, Katherine Wilson, Alomi O Parikh, Allison McCoy, Jessica Chang, Rasika Sudharshan, Shreya Gupta, Sandy Zhang-Nunes Cureus.2023;[Epub] CrossRef
(How) ChatGPT - Artificial Intelligence Thinks It Can Help/Harm Physiatry Jakub Jačisko, Viktor Veselý, Ke-Vin Chang, Levent Özçakar American Journal of Physical Medicine & Rehabilitation.2023;[Epub] CrossRef
Objective Tourette syndrome (TS) is a neurodevelopmental disorder characterized by the presence of motor and phonic tics. Blocking phenomena, characterized by arrests in motor activity causing interruptions in movements or speech, have also been described in patients with TS. In this study, we aimed to characterize the frequency and features of blocking tics in patients with TS.
Methods We studied a cohort of 201 patients with TS evaluated at our movement disorders clinic.
Results We identified 12 (6%) patients with blocking phenomena. Phonic tic intrusion causing speech arrest was the most common (n = 8, 4%), followed by sustained isometric muscle contractions arresting body movements (n = 4, 2%). The following variables were statistically related to blocking phenomena: shoulder tics, leg tics, copropraxia, dystonic tics, simple phonic tics, and number of phonic tics per patient (all p < 0.050). In the multivariate regression, the presence of dystonic tics (p = 0.014) and a higher number of phonic tics (p = 0.022) were associated with blocking phenomena.
Conclusion Blocking phenomena are present in approximately 6% of patients with TS, and the presence of dystonic tics and a higher frequency and number of phonic tics increase the risk for these phenomena.
Citations
Citations to this article as recorded by
Tics emergencies and malignant tourette syndrome: Assessment and management José Fidel Baizabal-Carvallo, Andrea E. Cavanna, Joseph Jankovic Neuroscience & Biobehavioral Reviews.2024; 159: 105609. CrossRef
Tourette syndrome research highlights from 2023 Andreas Hartmann, Per Andrén, Cyril Atkinson-Clement, Virginie Czernecki, Cécile Delorme, Nanette Mol Debes, Simon Morand-Beaulieu, Kirsten Müller-Vahl, Peristera Paschou, Natalia Szejko, Apostolia Topaloudi, Kevin J. Black F1000Research.2024; 13: 677. CrossRef
Tourette syndrome research highlights from 2023 Andreas Hartmann, Per Andrén, Cyril Atkinson-Clement, Virginie Czernecki, Cécile Delorme, Nanette Mol Debes, Simon Morand-Beaulieu, Kirsten Müller-Vahl, Peristera Paschou, Natalia Szejko, Apostolia Topaloudi, Kevin J. Black F1000Research.2024; 13: 677. CrossRef
Oromandibular tics associated with Tourette syndrome José Fidel Baizabal-Carvallo, Marlene Alonso-Juarez, Joseph Jankovic Journal of Neurology.2023; 270(5): 2591. CrossRef
Objective aaWilson’s disease (WD) is a rare genetic disorder of copper metabolism, and longitudinal follow-up studies are limited. We performed a retrospective analysis to determine the clinical characteristics and long-term outcomes in a large WD cohort.
Methods aaMedical records of WD patients diagnosed from 2006–2021 at National Taiwan University Hospital were retrospectively evaluated for clinical presentations, neuroimages, genetic information, and follow-up outcomes.
Results aaThe present study enrolled 123 WD patients (mean follow-up: 11.12 ± 7.41 years), including 74 patients (60.2%) with hepatic features and 49 patients (39.8%) with predominantly neuropsychiatric symptoms. Compared to the hepatic group, the neuropsychiatric group exhibited more Kayser-Fleischer rings (77.6% vs. 41.9%, p < 0.01), lower serum ceruloplasmin levels (4.9 ± 3.9 vs. 6.3 ± 3.9 mg/dL, p < 0.01), smaller total brain and subcortical gray matter volumes (p < 0.0001), and worse functional outcomes during follow-up (p = 0.0003). Among patients with available DNA samples (n = 59), the most common mutations were p.R778L (allelic frequency of 22.03%) followed by p.P992L (11.86%) and p.T935M (9.32%). Patients with at least one allele of p.R778L had a younger onset age (p = 0.04), lower ceruloplasmin levels (p < 0.01), lower serum copper levels (p = 0.03), higher percentage of the hepatic form (p = 0.03), and a better functional outcome during follow-up (p = 0.0012) compared to patients with other genetic variations.
Conclusion aaThe distinct clinical characteristics and long-term outcomes of patients in our cohort support the ethnic differences regarding the mutational spectrum and clinical presentations in WD.
Citations
Citations to this article as recorded by
Topographical metal burden correlates with brain atrophy and clinical severity in Wilson's disease Sung-Pin Fan, Ya-Fang Chen, Cheng-Hsuan Li, Yih-Chih Kuo, Ni-Chung Lee, Yin-Hsiu Chien, Wuh-Liang Hwu, Tai-Chung Tseng, Tung-Hung Su, Chien-Ting Hsu, Huey-Ling Chen, Chin-Hsien Lin, Yen-Hsuan Ni NeuroImage.2024; 299: 120829. CrossRef
ATP7B Gene Variant Profile İdentified by NGS in Wilson’s Disease Orhan Gorukmez, Taner Özgür, Ozlem Gorukmez, Ali Topak Fetal and Pediatric Pathology.2023; 42(6): 891. CrossRef
Objective Safinamide is a selective, reversible monoamine oxidase B inhibitor with demonstrated efficacy and tolerability in placebo-controlled studies and is clinically useful for patients with motor fluctuations. This study evaluated the efficacy and safety of safinamide as a levodopa adjunct therapy in Asian patients with Parkinson’s disease.
Methods Data from 173 Asian and 371 Caucasian patients from the international Phase III SETTLE study were included in this post hoc analysis. The safinamide dose was increased from 50 mg/day to 100 mg/day if no tolerability issues occurred at week 2. The primary outcome was the change from baseline to week 24 in daily ON-time without troublesome dyskinesia (i.e., ON-time). Key secondary outcomes included changes in Unified Parkinson’s Disease Rating Scale (UPDRS) scores.
Results Safinamide significantly increased daily ON-time relative to placebo in both groups (least-squares mean: 0.83 hours, p = 0.011 [Asians]; 1.05 hours, p < 0.0001 [Caucasians]). Motor function relative to placebo (UPDRS Part III) improved significantly in Asians (-2.65 points, p = 0.012) but not Caucasians (-1.44 points, p = 0.0576). Safinamide did not worsen Dyskinesia Rating Scale scores in either subgroup, regardless of the presence or absence of dyskinesia at baseline. Dyskinesia was largely mild for Asians and moderate for Caucasians. None of the Asian patients experienced adverse events leading to treatment discontinuation.
Conclusion Safinamide as a levodopa adjunct is well tolerated and effective in reducing motor fluctuations in both Asian and Caucasian patients. Further studies to investigate the real-world effectiveness and safety of safinamide in Asia are warranted.
Citations
Citations to this article as recorded by
Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study Noriko Nishikawa, Taku Hatano, Kenya Nishioka, Shin-Ichi Ueno, Shinji Saiki, Ryota Nakamura, Asako Yoritaka, Takashi Ogawa, Yasushi Shimo, Wataru Sako, Hideki Shimura, Yoshiaki Furukawa, Takanori Kamei, Takayuki Ishida, Nobutaka Hattori Journal of the Neurological Sciences.2024; 461: 123051. CrossRef
The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson’s Disease Carlo Cattaneo, Jaime Kulisevsky Advances in Therapy.2023;[Epub] CrossRef
Objective Embouchure dystonia (ED) is a task-specific movement disorder that leads to loss of fine motor control of the embouchure and tongue muscles in wind musicians. In contrast to musicians’ hand dystonia, no validated severity rating for ED exists, posing a major obstacle for structured assessment in scientific and clinical settings. The aim of this study is to validate an ED severity rating scale (EDSRS) allowing for a standardized estimation of symptom severity in ED.
Methods The EDSRS was set up as a composite score of six items evaluating audio-visual disease symptoms during the performance of three standardized musical tasks (sustained notes, scales, and fourths) separately for each body side. For validation, 17 musicians with ED underwent standardized audiovisual recordings during performance. Anonymized and randomized recordings were assessed by two experts in ED (raters). Statistical analysis included metrics of consistency, reliability, and construct validity with the fluctuation of the fundamental frequency of the acoustic signal (F0) (extracted in an audio analysis of the sustained notes).
Results The EDSRS showed high internal consistency (Cronbach’s α = 0.975−0.983, corrected item-total correlations r = 0.90−0.96), interrater reliability (intraclass correlation coefficient [ICC] for agreement/consistency = 0.94/0.96), intrarater reliability over time (ICC per rater = 0.93/0.87) and good precision (standard error of measurement = 2.19/2.65), and correlated significantly with F0 variability (r = 0.55–0.60, p = 0.011–0.023).
Conclusion The developed EDSRS is a valid and reliable tool for the assessment of ED severity in the hands of trained expert raters. Its easy applicability makes it suitable not only for routine clinical practice but also for scientific studies.
Elke Schipani Bailey, Sara J. Hooshmand, Negin Badihian, Paola Sandroni, Eduardo E. Benarroch, James H. Bower, Phillip A. Low, Wolfgang Singer, Elizabeth A. Coon
J Mov Disord. 2023;16(2):196-201. Published online May 24, 2023
Objective Multiple system atrophy (MSA) is characterized by urinary dysfunction, yet the influence of sex and gender on urinary symptoms and treatment is unclear. We sought to characterize sex and gender differences in the symptomatology, evaluation, and management of urinary dysfunction in patients with MSA.
Methods Patients with MSA evaluated at our institution were reviewed and stratified by sex.
Results While the prevalence of urinary symptoms was similar in male and female patients, incontinence was more common in females. Despite this, males and females underwent postvoid residual (PVR) measurement at similar rates. While catheterization rates were similar when PVR was measured, males were more than twice as likely to be catheterized than females in the absence of PVR measurement.
Conclusion Urinary symptoms are common in MSA, but their presentation differs between males and females. The difference in catheterization rates may be driven by a gender disparity in referrals for PVR, which can guide treatment.
Citations
Citations to this article as recorded by
In vivo cerebral metabolic and dopaminergic characteristics in multiple system atrophy with orthostatic hypotension Chenxi Xue, Xiaofeng Dou, Congcong Yu, Yan Zhong, Jing Wang, Xiang Zhang, Le Xue, Daoyan Hu, Shuang Wu, Hong Zhang, Mei Tian European Journal of Nuclear Medicine and Molecular Imaging.2024; 51(2): 468. CrossRef
Sex-related differences in the clinical presentation of multiple system atrophy Fabian Leys, Sabine Eschlböck, Nicole Campese, Philipp Mahlknecht, Marina Peball, Georg Goebel, Victoria Sidoroff, Florian Krismer, Roberta Granata, Stefan Kiechl, Werner Poewe, Klaus Seppi, Gregor K. Wenning, Alessandra Fanciulli Clinical Autonomic Research.2024; 34(2): 253. CrossRef
Mutations in the synaptic nuclear envelope protein 1 (SYNE1) gene are associated with substantial clinical heterogeneity. Here, we report the first case of SYNE1 ataxia in Taiwan due to two novel truncating mutations. Our patient, a 53-year-old female, exhibited pure cerebellar ataxia with c.1922del in exon 18 and c. C3883T mutations in exon 31. Previous studies have indicated that the prevalence of SYNE1 ataxia among East Asian populations is low. In this study, we identified 27 cases of SYNE1 ataxia from 22 families in East Asia. Of the 28 patients recruited in this study (including our patient), 10 exhibited pure cerebellar ataxia, and 18 exhibited ataxia plus syndromes. We could not find an exact correlation between genotypes and phenotypes. Additionally, we established a precise molecular diagnosis in our patient’s family and extended the findings on the ethnic, phenotypic, and genotypic diversity of the SYNE1 mutational spectrum.
Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort Sneha D Kamath, Vikram V. Holla, Prashant Phulpagar, Nitish Kamble, Ravi Yadav, Babylakshmi Muthusamy, Pramod Kumar Pal Movement Disorders.2024; 39(3): 628. CrossRef
Jaw Opening Myoclonus in Subacute Sclerosing Panencephalitis: A New Phenotypic Observation Divyani Garg, Vanshika Kakkar, Suvasini Sharma Journal of Movement Disorders.2024; 17(1): 106. CrossRef
Movement Disorders in Patients with Subacute Sclerosing Panencephalitis: A Systematic Review Divyani Garg, Sahil Patel, Charulata S. Sankhla, Vikram V. Holla, Vijayashankar Paramanandam, Prashanth L. Kukkle, Sanjay Pandey, Susanne A. Schneider, Pramod K. Pal Movement Disorders Clinical Practice.2024; 11(7): 770. CrossRef
Subacute sclerosing panencephalitis presenting as repeated extension of the neck: A case report Ravindra Kumar Garg, Imran Rizvi, Vikas Prabhu, Neeraj Kumar, Hardeep S. Malhotra, Praveen K. Sharma Annals of Movement Disorders.2024; 7(2): 138. CrossRef
Rebecca Hui Min Hoe, Fan Yang, Siew Kit Shuit, Glenn Khai Wern Yong, Ser Hon Puah, Jennifer Sye Jin Ting, Mucheli Sharavan Sadasiv, Thirugnanam Umapathi
J Mov Disord. 2023;16(2):217-220. Published online April 26, 2023